Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system

Geahča maid

• 295 Novel T-cell immunotherapeutics enable the selective generation of more potently cytotoxic CD19 chimeric antigen receptor T-cells (CAR-T cells) from CMV-specific cytotoxic T-cells
  Dahkki: Scott Garforth, et al.
  Almmustuhtton: (2023-11-01)
• Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
  Dahkki: Peter S. Chang, et al.
  Almmustuhtton: (2024-01-01)
• The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma
  Dahkki: Emaan Haque, et al.
  Almmustuhtton: (2024-12-01)
• Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
  Dahkki: Kimberly Veliz, et al.
  Almmustuhtton: (2024-06-01)
• Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
  Dahkki: Na Zheng, et al.
  Almmustuhtton: (2024-01-01)